← SynDRA
SAVOLITINIB
SynDRA canonical compound SYN0038091 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | MET |
|---|
| Mechanism of action | c-Met inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MET INHIBITOR
- Hepatocyte growth factor receptor inhibitor
Cross-references
Synonyms
- AZD-6094
- Volitinib
- AZD6094
- HMPL-504
- UNII-2A2DA6857R
- CHEMBL3334567
- 2A2DA6857R
- Savolitinib [INN]
- Volitinib(Savolitinib)
- Savolitinib [USAN:INN]
- GTPL9918
- SCHEMBL12489208
- EX-A845
- BDBM50023342
- ZINC149738712
- AKOS030526403
- DB12048
- compound 28 [PMID: 25148209]
- HY-15959
- AS-35250
- 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-
- KB-333895
- FT-0700162
- J-690125
- 4-{1-[(1S)-1-{imidazo[1,2-a]pyri
- HMPL 504
- AZD 6094
- HMPL504
- savolitinibum
- RefChem:884623
- DTXCID301542632
- Orpathys
- MFCD28359096
- Savolitinib (AZD6094)
- C17H15N9
- Volitinib dihydrochloride
- AZD6094 dihydrochloride
- Savolitinib dihydrochloride
- SAVOLITINIB [USAN]
Look up SAVOLITINIB in the interactive SynDRA portal →